In our continuous efforts to support antiviral discovery, research and development, ISAR announces a new partnership with the World Antiviral Congress (#WAC). This conference is sharply focused on the translational aspects of antiviral drug discovery and development, to bring new drugs to the market. Consistently with this focus, last year’s WAC speakers included an outstanding roster from a number of the most critical companies involved in all areas related to translational antiviral and viral vaccine research and development, including Gilead, Takeda, AstraZeneca, Bristol-Myers Squibb, Merck, Pfizer, GSK, Moderna, Ridgeback Biotherapeutics, Emergent, Genentech, Adaptive, Bioaxys, AVAC, altimmune, SinoBiological, Amgen, 10xGenomics, Luminex, Viiv technologies, NTx, InstillBio, Sartorius, PPD, Vaccitech, Marken, Selva, IndevR, 3T Bioscience, BalinBac, G.ST, vaxxinity, Geovax, Enochian, Verndari, Vaxes, Gritstone, Studylog, Agilent, CoCrystal, Horizons Global Solutions, RenBio, among others, together with an outstanding roster of academic and governmental leaders in these fields.
ISAR members will enjoy a 20% registration discount at the up and coming WAC2022 in San Diego, California. The meeting will take place from November 28 to December 1 at the Lowes Coronado Bay Resort, San Diego. For details and registration, please follow this link:
About ISAR NEWS
The official newsletter of the International Society for Antiviral Research
© Publications workgroup (Communications & Outreach Committee) and Luis M Schang, Editor